Understanding how certain enzymes help prevent DNA damage in cancer cells
Deciphering pathways involved in topoisomerase II turnover
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10992783
This study is looking at how certain enzymes help manage DNA in our cells and how we can control them to reduce damage, especially during cancer treatment, with the hope of finding better ways to make cancer therapies work more effectively and with fewer side effects for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10992783 on ClinicalTrials.gov |
What this research studies
This research investigates the role of type II topoisomerases, which are enzymes that manage DNA structure by introducing breaks to relieve tension. The focus is on how these enzymes can be regulated to minimize DNA damage, particularly in the context of cancer treatment. By studying the mechanisms that allow cells to avoid harmful DNA lesions caused by these enzymes, the research aims to uncover new strategies for enhancing the effectiveness of existing cancer therapies. Patients may benefit from insights that could lead to improved cancer treatments with fewer side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals undergoing treatment for cancer, particularly those receiving therapies that involve topoisomerase inhibitors.
Not a fit: Patients with non-cancerous conditions or those not receiving topoisomerase-targeting therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that minimize DNA damage and improve patient outcomes.
How similar studies have performed: Previous research has shown promising results in understanding the mechanisms of DNA repair and the role of topoisomerases in cancer, indicating that this approach has potential for success.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, JUNJIE — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: CHEN, JUNJIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug, anti-cancer therapy